lenacapavir

lenacapavir

Interactive Data Dashboards

Track the HIV & TB response

Key indicators, province breakdowns and downloadable graphs.

  • Spotlight’s top 9 health stories to watch in 2026

    From the limited rollout of a new HIV prevention jab to developments with new weight loss medicines, to high-stakes court cases relating to National Health Insurance (NHI), 2026 is set to be another tumultuous year in healthcare. Here are nine stories that Spotlight will keep a close eye on.

    ·

  • TIMELINE | The journey of HIV through science, struggle, activism, and hope

    From the first reported cases of HIV in 1981 to the latest breakthroughs in long-acting prevention, this Spotlight timeline traces key moments in the global and South African response to the virus. It highlights scientific milestones, political controversies, activism, and the human stories that shaped one of the most significant public health challenges of our…

    ·

  • Spotlight launches new HIV dashboard

    Spotlight has launched a new HIV dashboard and graph generator based on outputs from the Thembisa model. Our hope is that this dashboard will help the public and people working in healthcare to find important HIV numbers more easily. Please take a look and let us know what you think of it.

    ·

  • Breakthrough HIV prevention jab given green light in SA

    An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa’s medicines regulator. The approval helps to clear the way for a limited public sector rollout of the “game-changing” shot set to start in April 2026.

    ·

  • Twists and turns in the race to be SA’s first widely used HIV prevention injection

    The health department has plans to roll out lenacapavir, a twice-yearly HIV prevention injection, in a select group of public sector clinics by April 2026. Meanwhile, little progress has been made towards rolling out a two-monthly prevention injection, despite the four-year head start this product had on lenacapavir. Catherine Tomlinson reports.

    ·

  • IAS2025: Findings give hope for monthly HIV prevention pill

    An HIV prevention pill that could provide a month of protection per tablet has been given the green light to proceed to pivotal trials to test its efficacy. Elri Voigt reports on new findings on the pill that were presented at the International AIDS Conference.

    ·

  • South Africa’s AIDS response: Progress, challenges, and opportunities

    Ahead of World AIDS Day 2024, Professor Salim Abdool Karim and Dr Nikita Devnarain argue that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention alongside a well-functioning HIV treatment programme.

    ·

  • Why the fuss about long-acting antiretrovirals for HIV?

    HIV prevention injections that can provide two, or even six, months of protection per shot have arguably been the biggest HIV story of the year. Ahead of World AIDS Day, Professor Francois Venter assesses the state of play and the critical next steps with these potentially game-changing new tools in the fight against HIV.

    ·

  • Efficacy of 6-monthly HIV prevention jab confirmed in second major study

    In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works. Elri Voigt goes over the new findings and unpacks the licenses that are expected to facilitate the availability of generic versions…

    ·